enVVeno Medical Corp
Company Profile
Business description
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.
Contact
70 Doppler
IrvineCA92618
USAT: +1 949 261-2900
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
37
Stocks News & Analysis
stocks
Ask the analyst: How reliant are Guzman shares on international growth?
stocks
Nvidia: Back in business in China; Raising fair value estimate
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,890.80 | 74.40 | 0.84% |
CAC 40 | 7,822.00 | 99.91 | 1.29% |
DAX 40 | 24,370.93 | 361.55 | 1.51% |
Dow JONES (US) | 44,484.49 | 229.71 | 0.52% |
FTSE 100 | 8,972.64 | 46.09 | 0.52% |
HKSE | 24,498.95 | 18.81 | -0.08% |
NASDAQ | 20,885.65 | 155.16 | 0.75% |
Nikkei 225 | 39,901.19 | 237.79 | 0.60% |
NZX 50 Index | 12,905.41 | 150.82 | 1.18% |
S&P 500 | 6,297.36 | 33.66 | 0.54% |
S&P/ASX 200 | 8,639.00 | 77.20 | 0.90% |
SSE Composite Index | 3,516.83 | 13.05 | 0.37% |